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One of President Trump’s first actions on assuming office was to formally withdraw the United States from the Trans-Pacific Partnership (TPP), ironically 
an agreement driven more by American business interests 
than by those of the other 11 signatory countries. But the issues 
raised in our health impact assessment (HIA) of the TPP,1 
and the insightful commentaries it generated, have not died 
alongside the agreement. Regardless of the unpredictability 
of global politics during the Trump presidency, especially in 
terms of global trade relationships, the importance of ongoing 
analyses of the health impacts of trade has not abated. If 
anything, as several commentators note, it requires expansion, 
not diminishment.
From Probable to Actual Outcomes
Blouin,2 while noting how trade negotiators still tend to 
ignore health cost externalities in crafting new agreements, 
makes the important point that what is needed now are ex 
post analyses of how the 400 trade deals worldwide have 
affected health, both directly, and via social determinants of 
health pathways. Although there have been analyses of the 
impacts of such agreements on the price of medicines, studies 
on broader health determinants (such as poverty or income 
distribution) have been lacking apart from generic measures 
of economic integration, of which trade treaties themselves 
are only one component. The same point was raised by Walls 
et al3 who, while welcoming our ex ante assessment, recognize 
the need for ex post studies of actual rather than only potential 
impacts. We agree; and our group at this moment is proposing 
just such a study, using a novel database that quantifies the 
depth of liberalization within trade agreements to examine 
how a number of key health outcomes and public policy 
variables are affected. The policy component is important 
for two reasons. First, as Walls et al comment, we need to 
understand better the policies that might mitigate trade’s 
health-harmful impacts. Second, as Blouin underscores, we 
need better evidence on the role of such agreements (notably 
investment protection provisions) in creating ‘regulatory chill’ 
– a topic we have begun to examine (with a paper presently 
under review) but which we agree is one requiring more 
empirical analysis. Have trade and investment agreements 
simply become another tool in the regulatory capture of the 
state by powerful transnationals?
Investor State Dispute Settlement: Eliminate or Reform? 
Lencucha’s4 commentary, focusing on ISDS (investor state 
dispute settlement) provisions within the TPP, would answer 
Blouin’s question with a powerful affirmative. The litany of 
what Lencucha calls the ‘nefarious use’ of ISDS continues with 
little abatement. The TPP, of course, is not the only agreement 
to have such provisions, controversies around which have 
stalled (and almost completely undone) the Comprehensive 
Economic and Trade Agreement (CETA) between Canada 
and the European Union. CETA has become the testing 
ground for ISDS reform, with the Trump election knocking 
the US/EU ‘Trans-Atlantic Trade and Investment Partnership’ 
(or TTIP) off the radar. In the name of ‘legal scrubbing,’ 
Canada and the EU actually renegotiated the text of its 
original ISDS provisions post-signing, creating something 
called an ‘Investment Court System’ (ICS). 
As the commentary by McKee and Stuckler5 argue, the ICS 
improves on some of the procedural and interest-conflict 
provisions of ISDS, including greater transparency and a 
tightening of the bases upon which a dispute can be launched. 
That public health and broader civil society activism forced 
these ISDS reforms constitutes a small but important 
progressive step. The ICS’s ‘court system’ of ‘judges,’ however, 
has been rebuked by parts of the European legal community6 
and, more fundamentally, these ISDS reforms still fail 
to address the substantive question: Why should foreign 
investors be given greater rights than domestic investors or 
citizens in challenging government regulations that they 
think compromises the value of their investment? We may 
be less sanguine than Lencucha in thinking that abandoning 
ISDS completely would incentivize the strengthening of 
domestic court systems to avoid a kleptocratic state seizure 
of foreign assets. But the history of the use of ISDS suggests 
that it has not improved foreign investment in developing 
countries with weak judiciaries (its putative raison d’être) and 
has become, instead, a game played between lawyers, hedge 
funds and transnational corporations based in high-income 
countries against governments regardless of the impartiality 
of their domestic court systems. The ICS may slow the game 
down somewhat, but will not prevent it entirely, with an early 
analysis of its provisions finding that they would not have been 
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effective against a number of recent and highly controversial 
ISDS disputes.7
Broadening the Scope of Health Impact Analyses
Focusing less on what we did report on, McNamara8 points out 
some of the limitations in our assessment, such as insufficient 
attention to how certain provisions might potentially work 
for health benefits, and lack of detailed analysis of the 
implications of the TPP on employment. We agree on these 
points, even collaborating with her on their elaboration.9 We 
also share her concern that a general shortcoming of HIAs 
of trade and investment treaties is their preoccupation with 
traditional (if nonetheless important) health topics, such as 
unhealthy commodities, and drug prices or health services, 
while ignoring arguably more important health determinants, 
such as employment and environment. In her call for more 
attention to these ‘broader determinants of health’ McNamara 
also queries the limitations of HIA as a tool for future analyses 
of the trade and health nexus. We are partly in agreement, as 
our own study adopted the broad structure of HIA but used 
multiple methods that, ultimately, created a synthetic analysis 
of the agreement’s probable health effects. Our study was less 
about being an HIA per se than using appropriate methods to 
address the questions we had posed, even if the methods and 
findings were packaged as an ‘impact assessment.’ 
In that sense, we are sympathetic to the critique made 
by Muntaner and Mahabir10 of our HIA’s ‘textualism’ and 
‘pragmatic approach.’ Much of our related work to the HIA 
follows some of the methodological innovations that they 
suggest reside in a scientific realist approach, including 
theory testing and use of multiple methods to make the ‘black 
box’ of policy formulation transparent’ including the role of 
‘ideology, resistance, and political power’ in policy outcomes. 
Perhaps more than these two commentators, however, we 
are also drawn to the usefulness of constructivist theory in 
understanding how these same three threads manifest as 
agreement or conflict in differing economic contexts, which 
forms the core of a related study on health and foreign policy 
in which we are actively engaged.11 But we share their same 
core argument that treaties such as the TPP embody in their 
design, text and probable impacts the interests of those 
economic elites who play a major role in their development, 
some evidence of which we offered elsewhere.12-14 
The Trans-Pacific Partnership: Semi-official Zombie Status
The points raised in these various commentaries, as well as 
our own analysis of the TPP, may seem moot given Trump’s 
summary execution of the agreement. But, along with 
the presumed demise of neoliberalism and the return of 
mercantilist protectionism that have been much heralded 
since the contrarian outcomes of the Brexit vote and the US 
presidential election, such conclusions may be premature. 
There are powerful capitalist interests in the United States 
that would be seriously harmed if that country’s borders 
did start to close to trade and the new Washington regime 
begin to shred the ‘new constitutionalism’ of its many global 
trade and investment treaties. Three-quarters of the Chinese 
products entering the United States, accounting for much 
of China’s touted trade-surplus and a key target in Trump’s 
populist cross-hairs,15 are actually American goods whose 
manufacturing had been outsourced to reduce labour and 
environmental protection costs.16 Many US industries 
similarly take advantage of immigrant labour from Mexico, 
and highly-subsidized American corn producers benefited 
from the North American Free Trade Agreement’s (NAFTA’s) 
evisceration of Mexico’s small-hold corn farming sector (and 
one of the motivators for mass migration northwards).17 The 
extent of global market integration achieved by neoliberalism’s 
forty year-run is different from that of the earlier era of 
economic globalization in the late 19th century to which our 
present time is frequently equated (including how its collapse 
ushered in two world wars). Today’s vertically integrated 
production chains and hypermobile capital will make it much 
harder to unravel or restrain economic integration. 
This is not to say that a Trump administration would 
necessarily want to do so. Shortly after winning the election, 
Trump referred to a strategy of creating new bilateral trade 
deals to replace the ones he campaigned against. How 
different would these be from the now defunct TPP? Would 
they really exclude ISDS? Reduce the protectionism of 
expanded intellectual property rights? Weaken US oversight 
of other countries’ regulatory regimes? Have stronger labour 
and environmental protection measures? Improbable, to say 
the least, especially given that a recently published text-as-
data analysis of the TPP found it to be overwhelmingly drawn 
from prior US trade agreements that reflected US economic 
and political interests.18 Just as several of the original TPP 
countries have carried on with their own ratification of 
the treaty, indicating support for its economic policies 
that could be resurrected in other agreements, the new US 
administration might simply export what it likes about the 
TPP into other trade negotiating venues while appearing to 
have scrapped the deal.
The TPP may yet prove to be a zombie, continually rising from 
the dead in only vaguely altered form. The real possibility of 
this renders our original analysis of the health impacts of 
the agreement, and the commentaries offered by colleagues 
in response, important points for ongoing public health 
lobbying efforts. As Thow and Gleeson19 emphasize, this is 
especially so since the new uncertainty of a (post?)-neoliberal 
era offers us an opportunity to argue more effectively for what 
a health-enhancing, socially just and ecologically-protective 
trading regime could (or should) look like. As they conclude, 
this will require greater trade policy and research capacity 
within public health and, more importantly and echoing 
a point consistent across all of the commentaries, a greater 
understanding of the political and economic power relations 
that set such trade and investment agendas in the first place.
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